ACBFF - search results

If you're not happy with the results, please do another search

2 663

In the past year, the marijuana industry has been a monster in terms of growth. Many investors have decided to jump right in to this new industry with profits hitting all time highs. It is not out of the ordinary to see some marijuana stocks that have doubled or even tripled in value over the past 12 months.

With an industry that is expected to grow from around $5 billion to a whopping $17 billion by 2021, why not jump right in? Those numbers put the industry at a 300% legal sales growth with opportunities unexplored including new states legalizing the drug, organic growth within legal states, and the opportunity to move the black market into legal channels. The opportunity for marijuana is incredible. Here’s four stocks that have grown a substantial 10% in the last week.

1.Cara Therapeutics (+12.8%)
A market favorite for its large, quick, gains, Cara Therapeutics (NASDAQ: CARA) had unfortunately lost more than half of its market value in a two-week timeframe. Last week, Cara unexpectedly found its place and grew almost 13%.

One major piece of news seems to be the cause here. On July 12th Cara announced it data for its phase 1 trial of oral CR845, a treatment for pain and pruritus (itching) in patients with chronic kidney disease who are undergoing hemodialysis. All of the data was very promising.

2. Aphria (13.2%)
One of the Canadian giants in the industry, Aphria (NASDAQOTH: APHQF) had an exceptional week, growing over 13%. Many speculate that this is due to its fourth-quarter and full-year results for the fiscal year of 2017. The company did report a loss however in its fourth-quarter report but the $5.5 million is all accounted for in the companies new plans for expansion and growth. The largest strong spot of their report was a 25% decrease in all-in cash costs from 2016 to $1.31 a gram. As demand rises and costs fall, the company is expected to continue this growth trend.

3. Aurora Cannabis (+16.1%)
The largest gainer of the week among marijuana stocks with a 16% gain, was Aurora Cannabis (NASDAQOTH: ACBFF), yet another Canadian medical-cannabis producer. Aurora happens to be one of Aphria’s largest competitors. Aurora recently announced that it is in the process of developing what they call ‘the Aurora Sky project’. The project is essentially an 800,000 square foot facility that the company claims will be the most advanced and automated in the world. It is scheduled to be completed early next year.

One of the main reasons why Aurora skyrocket is an announcement that it would move from the TSX Venture Exchange to the much larger Toronto Stock Exchange. This move comes from a significant boost in the companies market cap over the past year, and could be just the jump investors need to get their feet wet.

0 1044

The company Aurora Cannabis (NASDAQOTH: ACBFF) has provided a solid platform for investing in the recent months. Shares of this canadian company are up almost 400% in the past year.

Does all this recent gain make Aurora Cannabis an intelligent buy? Here’s a few insights that investors should know before dipping their portfolio into this hot marijuana stock.

Why has this stock soared so much in the recent months? After Aurora’s initial public offering in 2014, the stock plummeted throughout the next year. Despite receiving a highly anticipated license to provide medical marijuana from the Canadian government in November 2015, its stock performance did not reflect the new information.

In the summer of last year, things started to improve for the Canadian company despite the country allowing citizens to grow their own medical marijuana. The improvement is attributed to three pieces of news which generated excitement amongst potential investors.

The first was the announcement that the company would be acquiring CanvasRx, which at the time was Canada’s largest medical marijuana patient outreach service. This acquisition put Aurora at a great advantage as they now had potential to reach a much larger clientele base. Second, the company received financing for net proceeds of around $23 million which the company stated it would use for expanding its operations. Lastly, Aurora’s revenue topped $1 million for the first time in company history.

Around this time, the public became more inclined to invest in marijuana stocks as the industry began to take off. This was partly due to several U.S. states legalizing cannabis recreationally and medically.

All of this is behind the opportunity for the legalization of recreational cannabis in Canada. Prime Minister Justin Trudeau has pushed incredibly hard to fulfill one of his campaign promises allowing recreational marijuana throughout the country. If his current efforts come to fruition, marijuana could be recreationally legal in Canada by July 2018.

All of these efforts provide a basis for Aurora to reach new high’s and in addition provide investors with a strong base for whether or not to add Aurora to their portfolio’s.

0 4941
marijuana-stocks- benjamins

The marijuana industry is growing at a rapid pace, and investors have surely taken notice. Much more marijuana stocks have witnessed their valuations increase substantially, or maybe run even higher, over the trailing 12-month period.

Stemming from a 2016 Gallup poll and an April 2017 CBS News poll, the percentage of those who were receptive to seeing recreational cannabis legalized nationally which has surged to a respective 60% and 61%, both all-time highs. By comparison, Gallup’s 1995 poll showed just 25% approval for such a play, while the CBS News poll was a full 21-percentage-points lower just six years ago. The public wants change at the federal level, and investors are trying to beat that change by purchasing marijuana stocks.

The sale of legal marijuana has also risen. Investment firm Cowen & Co. is looking for $50 billion in legal annual cannabis sales by 2026, while a more recent report from Marijuana Business Daily implies that legal U.S. sales could triple between 2017 and 2021, to more than $17 billion. You’d probably struggle to find such consistent growth in any other industry or sector.

Which marijuana stock could hit $1 billion in sales first?

Yet, there are dozens of marijuana stocks to choose from, and they’re clearly not all going to be winners. The top performers, assuming marijuana remains legal in select states and that it gains broader approval in Canada and Mexico, are probably going to be the pot-based businesses that can really ramp up revenue and turn a healthy profit.

If there is a significant bench mark out there for marijuana stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry. But which marijuana stock has the best chance at being first to $1 billion in annual sales?

1. GW Pharmaceuticals
Considered the most sensible choice is cannabinoid-based drug developer GW Pharmaceuticals (NASDAQ: GWPH), which also happens to be the largest pot stock by a mile in terms of market cap.

What makes GW Pharmaceuticals so unique is its currently experimental cannabidiol therapy Epidiolex, which hit its primary endpoint in a pivotal phase 3 trials for two rare types of childhood-onset epilepsy. In both its Dravet syndrome and Lennox-Gastaut syndrome trials, Epidiolex led to a statistically significant reduction in seizure frequency compared to the placebo.

The success of these studies puts the company on track to get Epidiolex approved by the Food and Drug Administration (FDA), though nothing is ever a guarantee when it comes to the FDA. Assuming some potential for label expansion, Epidiolex could very well hit $1 billion in peak annual sales, if not a tad higher.

2. Corbus Pharmaceuticals
Corbus Pharmaceuticals (NASDAQ: CRBP) is considerably more of a wildcard than GW Pharmaceuticals, but if one specific clinical trial goes its way, it could easily leap to $1 billion in annual sales.

Corbus’ pipeline consists of a solitary drug known as anabasum, which is a synthetic oral endocannabinoid-mimetic drug that binds to the CB2 receptors expressed on immune cells and fibroblasts. Its drug is being tested in four indications, but one stands out head and shoulders above the rest: cystic fibrosis (CF). There are few drugs to treat CF, and most that are FDA approved target a very specific mutation, making their impact limited within the CF community. Anabasum is believed to have a global anti-inflammatory effect, meaning it could be taken by most, or all, CF patients.

3. Canopy Growth Corp.
Another seemingly logical marijuana stock that could thrive is Canopy Growth Corp. (NASDAQOTH: TWMJF), a producer and retailer of medical cannabis products and oils in Canada. Medical weed has been legal in Canada since 2001.

Canopy Growth has been a busy bee of late on the acquisition front. It completed its acquisition of Mettrum Health earlier this year, and it acquired a 472,000 square foot facility that includes its current corporate headquarters.

Growth by acquisition gives the company immediate access to more medical marijuana patients and the ability to rapidly expand its growing capacity.

4. Aphria
One of Canopy Growth’s largest competitors in the Canadian medical marijuana producing and retail business is Aphria (NASDAQOTH: APHQF). Aphria has the distinction of being the most prominently profitable marijuana stock, with the company reporting five consecutive quarterly profits.

Unlike Canopy Growth, Aphria is doing things organically. It’s been funding expansions of its existing grow capacity, and is currently working on its most aggressive growth initiative to date, Phase IV.

5. Aurora Cannabis
And how can we forget Aurora Cannabis (NASDAQOTH: ACBFF), yet another of Canada’s medical cannabis producers and retailers. Aurora Cannabis has lagged its peers in recent profits due to its expansion-based spending.

Like Aphria, Aurora Cannabis is all about organic development. Aurora Cannabis has touted its Aurora Sky project, which will increase its cultivating capacity nearly ninefold, as the most technologically advanced and automated cannabis-grow facility in the world, when completed.

0 898

In February, the cannabis industry recorded a major milestone when Australia became the first continent to legalize medical marijuana.

The legislation amended the Narcotic Drugs Act and allows for the cultivation of marijuana for medical and scientific purposes. Following the passing of this legislation, Australian Health Minister Sussan Ley made the following statement:

“This is an historic day for Australia and the many advocates who have fought long and hard to challenge the stigma around medicinal cannabis products so genuine patients are no longer treated as criminals. This is the missing piece in a patient’s treatment journey and will now see seamless access to locally-produced medicinal cannabis products from farm to pharmacy.”

iCAN Australia is Born

Australia represents a new opportunity for cannabis companies and yesterday, iCAN: Israel-Cannabis entered the market by forming a joint venture with LeafCann Research and Advisory. The partnership, iCAN: Australia will collaborate on a range of initiatives including medical cannabis research, innovation, acceleration, and education.

iCAN: Israel-Cannabis CEO Saul Kaye stated, “We are thrilled to partner with LeafCann to form iCAN: Australia. Our collaboration will bring world-class cannabis products to the Australian market as well as accelerate our collaborative research and development of new products for a range of indications.”

LeafCann’s practitioner education program will be incorporated into iCAN’s product offerings and distributed by iCAN. iCAN: Australia will take a significant interest in CannaTech Australia, a medical cannabis summit modeled after CannaTech’s events in Israel.

Canadian Titans Have the Early Mover Advantage

Although iCAN is not the first company to target the Australian cannabis market, it has taken a different approach when compared to the other companies that have entered the market.

Earlier this year, Cann Group announced that Aurora Cannabis (ACB.V) (ACBFF), a licensed medical cannabis producer in Canada, acquired 19.9% of the company ahead of its initial public offering.

Canopy Growth (WEED.TO) (TWMJF), the largest licensed medical cannabis producer in the world also entered the Australian medical cannabis industry through a partnership with AussCann (ACNNF). Canopy Growth will help AussCann increase market share and capitalize on the Australian cannabis market.

Global Expansion Continues

Marijuana legalization may not be a top priority for the United States right now, but change is occurring all over the world. The global marijuana industry has gathered support from many high-ranking officials over the last two years which has increased overall support for the reform of restrictive laws.

Progress toward this goal is hampered by political realities, such that cannabis is still classified as a Schedule I substance. It is time for change and for the authorities to recognize its medical benefits and to remove some of the restrictions that are not supported by scientific research.

Not only is this a medical necessity, but it just makes good business sense.

Authored By: Jason Spatafora

0 1708

2017 has been a year to remember and we are not even at the mid-point yet…

From the largest country in the European Union to entire continents, 2017 has been highlighted by the opening of new, major cannabis markets. This theme has been consistent over the last few years, and it is just getting started.

Australia is Becoming a Hotspot for Cannabis Businesses

In February, the cannabis industry recorded a major milestone after the Australian Parliament passed a measure which made it the first continent to legalize medical marijuana.

Cann Group Limited (ASX: CAN) was the first Australian company to be licensed by the Office of Drug Control for commercial medical cannabis cultivation and production. The company has facilities in Australia’s northern and southern region and is currently expanding both of its facilities to satisfy expected future demand.

Cann Group’s expansion project is fully funded and the company is focused on completing the buildout of its facilities, securing licenses for expansion purposes, and executing on its business plan.

In late May, Cann Group received the necessary permits to commence cultivation and will plant their initial crop in the next few days. The company expects to harvest its initial crop in early August if everything goes to plan.

Canadian Producer Set Sights on Australia

In March, Cann Group announced that Aurora Cannabis (ACB.V) (ACBFF), a licensed medical cannabis producer in Canada, acquired 19.9% of the business and became the cornerstone investor ahead of its initial public offering (IPO).

Another titan of the industry, Canopy Growth (WEED.TO) (TWMJF) has also entered the Australian medical cannabis industry through a partnership with AussCann (ACNNF). Canopy Growth is the largest licensed medical cannabis producer in Canada and the company will help AussCann increase market share and capitalize on the Australian cannabis market.

Canopy is not only one of AussCann’s largest shareholders but they have also granted them royalty-free access to their intellectual property as it relates to cultivation, supply, and manufacturing of medicinal cannabis.

The Marijuana Train Has Left the Station

Marijuana legalization may not be a top priority for the United States right now, but change is occurring all over the world. The global marijuana industry has gathered support from many high-ranking officials over the last two years which has increased overall support for the reform of restrictive laws.

Progress toward this goal is hampered by political realities, such that cannabis is still classified as a Schedule I substance. It is time for change and for the authorities to recognize its medical benefits and to remove some of the restrictions that are not supported by scientific research.

Not only is this a medical necessity, but it just makes good business sense.

Authored By Micheal Berger

0 2141

The Canadian cannabis industry should see even stronger growth in the back half of 2017 after Health Canada announced a major change to its rules that will streamline the application process and increase overall cannabis production.

Under the new regulations, licensed medical cannabis producers can better manage production to meet demand as they are now able to increase production within their facility to the maximum they are authorized to store, based on the capacity and security level of their vault(s) or safe(s).

This is a significant change to the Health Canada’s rules and licensed producers will benefit from this development. Several Canadian cannabis companies have announced important developments since this change was made and we want to highlight some of these announcements.

CW Improves Portfolio of Streaming Partners

Yesterday, Cannabis Wheaton (CBW.V: TSX Venture) (KWFLF) and ABcann Global Corporation (ABCN.V: TSX Venture) announced a binding interim agreement to fund the construction of a 50,000 square foot cultivation facility at ABcann’s proposed facility in Napanee, Ontario known as the Kimmett facility.

Under the agreement, Cannabis Wheaton has agreed to invest $30 million in ABcann as follows:

  • On the date that is the earlier of 10 days of the final closing of Cannabis Wheaton’s previously announced financing or by June 30th. The company will buy $15 million of common stock at $2.25 a share
  • On the date that is the earlier of 10 days of CW raising an aggregate of $150 million or March 31, 2018. Cannabis Wheaton will subscribe for an additional $15 million at a price  equal to the greater of two times the 10 day volume average trading price of ABcann at the relevant time or $2.25.

Upon completion of the $30 million investment, and upon accepting ABcann’s construction budget and timeline for the new production facility, Cannabis Wheaton will provide funding to complete the construction of it. In return, Cannabis Wheaton will receive 50% of the proceeds (net of certain costs) of future wholesale or retail sales completed by ABcann with respect to cannabis produced in the new production facility. Cannabis Wheaton’s entitlement to the allocation will not start until after the completion of the $30 million investment.

Aurora Expands International Presence into Germany

On Friday, Aurora Cannabis (ACB.V: TSX Venture) (ACBFF: OTCQX) announced that it was acquiring Pedanios GmbH, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union (EU).

The market responded mixed to this development and Aurora Cannabis came off its highs ended the day up less than 2%. This was a significant development for the company as it now is leverage to three legal cannabis markets (Canada, Australia, and Germany).

Since December 2015, Pedanios has been importing, exporting, and distributing medical cannabis into and within the EU. The company holds all relevant licenses and permits and is a federally licensed medical and narcotic wholesale and GMP inspected narcotic import business.

In March 2017, when Germany’s new law came into effect Pedanios’ monthly sales immediately doubled and growth continues to accelerate as Germany’s new regulations have made it much easier for its 80 million citizens to access medical cannabis.

Mobile Payment App Enters Cannabis Industry

Glance Technologies Inc. (GET.CN: OTC) (GLNNF) entered the legal cannabis industry after agreeing to license its mobile payment technology to Cannapay Financial for $1,000,000. Cannapay is developing a mobile payment app that will allow users to order products from their phones, tablets or computer and have them delivered to their physical location in compliance with local rules and regulations.

Pursuant to the agreement, Cannapay was issued a non-exclusive global license to white label Glance’s mobile payment processing platform and its anti-fraud technology for the legal cannabis industry. The license has an initial term of 10 years and is renewable for two additional 10 year periods. Glance will receive a 50% royalty on the revenue from all sub-licenses and additional fees for any development work required for customization/operation of the Cannapay platform.

Glance Technologies owns and operates Glance Pay, a streamlined payment system that revolutionizes how smartphone users choose where to dine, order food, settle bills, access digital receipts, earn great rewards, and interact with merchants. The Glance Pay mobile payment system consists of proprietary technology, which includes user apps available for free downloads in IOS (Apple) and Android formats.

This is an interesting development within the Canadian cannabis industry and will monitor how the market responds to these announcements from the sidelines. While we view this area as a major global opportunity, we are cautious and want to monitor how the company continues to execute.

Biotech Firm Enters Canadian Cannabis Industry

One of the Canadian cannabis firms under pressure has been Revive Therapeutics Ltd. (RVV.V: TSX Venture) (RVVTF).  Despite the shares being up more than 70% so far this year, the shares are down more than 33% in the last quarter and will monitor how the market responds to its  sponsored research agreement with the University of Wisconsin-Madison.

Under the agreement, Revive will work with the university to evaluate a novel drug delivery technology with a focus on cannabinoids for the potential to treat various diseases.

The research program will be led by Jess D. Reed, Ph.D., Professor of Animal Sciences at the University of Wisconsin-Madison. His team will evaluate the role and potential use of a chitosan-tannins based formula for the delivery of cannabinoids.

Although we are favorable on this development, we are cautious with Revive and continue to prefer Canadian companies like Emblem Corp (EMC.V) (EMMBF), which also has a biotech strategy to complement its legal cannabis sales strategy.

Disclaimer: Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable

marijuana stocks

A Revolutionary Cannabis Investment?

Some of the greatest investment minds in the world say, “You invest in management.” And since the birth of, few management personnel have shined brighter than Cannabis Wheaton Income Corp. CEO Chuck Rifici. Mr. Rifici has accomplished with Cannabis Wheaton something that no other cannabis industry CEO has. The business model he has implemented is something that we feel every marijuana investor MUST know about. Cannabis Wheaton (KWFLF)(CBW.V) provides a very unique opportunity for marijuana investors by greatly reducing risk while still maintaining tremendous upside potential.

But before we explain the Cannabis Wheaton business model and why we feel EVERY investor should know about it, let’s first take a look at Chuck Rifici. Because as we said earlier, “you invest in management.” And there may not be a more recognizable managerial figure who has done more for the marijuana industry than Mr. Rifici.

Invest in Management

Chuck Rifici is responsible for co-founding and taking public the largest full-scale producer of government-sanctioned marijuana as its CEO in April 2014; a company by the name of Tweed Inc. whose name later changed to Canopy Growth Corp. (TWMJF)(WEED.TO). To this day, Canopy Growth remains the largest public cannabis company with a staggering market cap of approximately $1Billion. In 2016, WEED hit $17.86 approximately 550% higher than the IPO price. It is widely agreed to be the most successful marijuana company to go public and is seen as the benchmark and leader of the industry.

Take a look at how WEED stock has performed over the last 2 years:

marijuana stocks

When considering an investment in any company, it’s important to look at the management team. Who is leading the ship? Is this their first rodeo? Or have they already proven successful in bringing a company to market that has built shareholder value? Well, Chuck Rifici’s track record with co-founding Tweed speaks for itself and gives Cannabis Wheaton shareholders confidence that they have a marijuana industry trailblazer leading their ship.

But Rifici’s resume is filled with much more than just Tweed. In 2011, Rifici was appointed CFO of the Liberal Party of Canada by interim party leader Bob Rae. In 2014, Rifici was also named to the Top Forty under 40 by Ottawa Business Journal, named Alumnus of the Year by the University of Ottawa Faculty of Engineering, and received the Exceptional New Business Award by the Ottawa Chamber of Commerce.

Rifici also sat on the Board of marijuana starlets Supreme Pharmaceuticals (SPRWF) (SL.CN), Aurora Cannabis (ACBFF) (ACB.V), and CannaRoyalty (CNNRF) (CRZ.V). These board positions helped Rifici keep his ear to the ground, expand his network, and gain insight to the marijuana industry in both Canada and the U.S. He actually just resigned from his Supreme Pharma and Aurora Cannabis Board seats because of a slight conflict of interest but mostly to focus all of his time and energy towards building Cannabis Wheaton into a revolutionary cannabis company.

Cannabis Wheaton’s Streaming Model—Revolutionizing Cannabis Investment

Cannabis Wheaton is the first company to bring a streaming business model to the marijuana industry. This unique model can greatly reduce risk for investors while maintaining tremendous upside potential from a booming industry. Streaming business models are normally found in the mining industry and refer to when a company strikes a deal with a miner to purchase all or part of its future metal production in exchange for upfront cash. Perhaps the most notable example is silver giant Silver Wheaton (NYSE: SLW). This works well because mining is a very cash intensive business and requires a lot of upfront capital. And the cannabis industry is about to undergo a massive expansion that will be an serious capital burden on current marijuana producers.

Rifici has said that the marijuana industry must increase total production by 10 times the current rate in order to keep pace with the increased demand for marijuana once the drug is legalized for recreational use. Producers are barely keeping up with cannabis demand from just medical marijuana users, never mind when legal recreational use goes into effect.

Currently, there is only 1.4 million square feet of licensed medical marijuana production facilities in Canada. According to Rifici, 14 million square feet is needed to satisfy the upcoming demand. Such a massive expansion is a major financial burden and carries great risk for companies trying to expand so much so quickly. And that is where the opportunity lies for Cannabis Wheaton.

“We’re going to see tremendous growth in the industry…There have been a lot of announced expansions that fill maybe a third of that gap. But there’s still 6 or 7 million square feet that needs to be built out,” said the Rifici.

Under the streaming model, Cannabis Wheaton will provide marijuana producers with the necessary capital to expand their operations in exchange for a minority equity stake in the company and a portion of their future production at an agreed upon discounted price. The company will also provide their partners with guidance and expertise on facility construction, cultivation, and the licensing process. Rifici has brought to Wheaton several of the early key members of Tweed including the top cannabis legal team in Canada that has helped half a dozen Licensed Producers (LPs) obtain their licenses.

Cannabis Wheaton has already signed 16 streaming deals with 14 partners across 6 different provinces of Canada. Their partners’ credentials include:

  • 2 sales licenses.
  • 3 cultivation licenses.
  • 4 affirmation letters.
  • 5 advanced pre-affirmation stage applicants.

Through these agreements, Cannabis Wheaton already has access to 1.3 million square feet of cultivation by 2019, 30,000 registered medical marijuana patients, and nearly 40 medical cannabis clinics.

One agreement we feel worth mentioning specifically is the company’s deal with Broken Coast Cannabis Ltd., a British Columbia based medical cannabis producer that has established itself as a top provider of high grade cannabis products. Broken Coast’s clean tech production methods and systems deliver consistent premium cannabis. The company was also recently awarded one of the few 18-month Access to Cannabis for Medical Purposes Regulation (ACMPR) licenses, which is a testament to its compliance record.

Broken Coast and its entities will utilize the experience and capital of Cannabis Wheaton to accelerate expansion and scale production in a short period of time. Under the terms of the agreement between the companies, Broken Coast will source a proposed site to complement their current site. The parties expect the new location to accommodate at least 100,000 square foot state-of-the-art cannabis cultivation facility.

Broken Coast will operate the new facility in accordance with its industry best practices and the two companies will share the proceeds with Cannabis Wheaton receiving 49% of the product output.

5 Reasons to Consider Cannabis Wheaton

  1. Licensed Producer Diversification- Because the company is working with such a wide range of cannabis cultivation companies and receiving both an equity stake in those companies and a percentage of the end product, shareholder risk is spread out amongst several companies rather than just one.
  2. Exposure to Tremendous Upside- Usually, reducing risk results in reduced potential reward, too. But not in this case. Even with the reduced risk, shareholders are exposed to the explosive industry expansion that Rifici explained as being a 10x expansion. Current cannabis revenue numbers in Canada will pale in comparison to what we see once legal recreational use goes in effect. Cannabis Wheaton will hold an equity stake in many producers as well as owning portions of the end product at a discounted price.
  3. Geographic Diversification- Cannabis Wheaton has signed agreements with partners across 6 different provinces in Canada. This brings exposure to several different markets and acts almost as a loophole for the company to take advantage of a few question marks the industry has regarding distribution.
  4. Proven Business Model- The streaming business model has already been proven successful for some of the largest metal miners in the world. Silver Wheaton, a streaming company with a market cap of approximately $10Billion, went to this model because they generally have a bullish outlook on the price of silver. So, it makes sense for them to fund a miner’s drilling operations and expansion to purchase the future metal output at a steep discount. Similarly, Rifici and Cannabis Wheaton have a bullish outlook on the production rate and revenue numbers for marijuana in Canada expecting a 10x expansion of the industry. So, it makes sense to help fund the expansion in return for equity ownership and a portion of the end product.
  5. Successful Management- The team behind Cannabis Wheaton has already taken the largest producer of government-sanctioned marijuana public. And it was and remains the most successful IPO in the cannabis space and true leader of the industry. 


Ever since Rifici co-founded Tweed and brought the cannabis juggernaut public in 2014, investors wondered what his next project would be. Rifici said he is proud of what he built with Tweed but was ready to put the past behind him.

“I’m essentially moving on to what I think are far better opportunities in the space,” said the Cannabis Wheaton CEO.

It’s hard to imagine what opportunities could be more successful than a $1Billion market cap, top marijuana producing, cannabis leader that gained 550% from its IPO. But if anyone knows an opportunity in the marijuana space when they see one it’s Chuck Rifici.

Licensed Producers are already having trouble keeping up with demand from about only 130,000 registered medical marijuana patients. When legal recreational use goes into effect, demand is going to skyrocket. The current 1.4 million square feet of cultivation facility space simply isn’t going to cut it. Not even close. The entire industry is racing to undergo a massive expansion that will see cultivation space increase by about 10 times. That type of expansion is extremely costly and carries great risk for individual producers.

However, with their streaming business model, Cannabis Wheaton is de-risking the expansion while still giving investors exposure to the booming industry growth. With 16 agreements already inked with 14 different partners across 6 different provinces, Cannabis Wheaton could very well be revolutionizing the way investors capitalize on the cannabis industry.


Disclaimer: Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.


The Canadian stock market was closed for Victoria Day yesterday and today, three marijuana stocks reported several significant developments. We have highlighted these developments below to help you focus on important trends sweeping the industry.

New Cannabis IPO to Raise $50+ Million

One of newest and most differentiated Canadian cannabis producers, Cannabis Wheaton (CBW.V: TSX Venture) (KWFLF) announced a $50 million private placement and engaged a syndicate of agents co-led by Eight Capital and Canaccord Genuity.

The firm is selling special warrants and convertible debenture units and will use the net proceeds for general corporate purposes, for the financing of its streaming partners pursuant its streaming agreements, and for general and administrative expenses.

Cannabis Wheaton is off to a great start after the company reported that MMCAP International Inc. SPC intends to subscribe for up to $20,000,000 of the offering. The offering is expected to occur on June 21st and the company granted the underwriters an over-allotment option which increases the offering to $57.5 million.

Cronos’ Breaks Ground on a Brand New 315,000 sq. ft. Facility

Today, Cronos Group’s (MJN.V: TSX Venture) (PRMCF) wholly-owned licensed producer, the Peace Naturals Project broke ground on a 315,000 sq. ft. expansion that includes a 286,000 sq. ft. production facility, a 28,000 sq. ft. greenhouse, and an additional 1,200 sq. ft. extraction lab.

Upon completion, the facility is expected to be the largest purpose-built indoor cannabis production facility in the world. The facility is expected to complete by November and fully operational by summer 2018. This expansion will bring Peace’s total estimated production capacity to 40,000 kg a year.

The facility is designed to GMP certification standards and will include:

  • An area for proprietary genetic breeding
  • Pharma lab for cannabinoid and terpene extraction, identification, and formulation
  • R&D space for analyzing metabolite enhancement and new lighting technologies
  • Tissue culture laboratory
  • Industrial-grade kitchen
  • Processing infrastructure that supports production from other facilities

Cronos is breaking ground on the greenhouse today and the facility will be used to collect data and implement advanced cultivation techniques that can be replicated at its other production facilities. The company’s extraction lab will augment capabilities in both purification and recombination of cannabinoid compounds to create innovative formulated products. The greenhouse and lab are expected by the end of the summer.

Aurora to Supply Resources to Support a Groundbreaking Legal Case

Today, the Canadians for Fair Access to Medical Marijuana (CFAMM) reported an investment by Aurora Cannabis (ACB.V) (ACBFF) that is of a different nature than its prior investments.

CFAMM announced that Aurora has committed financial and other resources to support Gordon Skinner’s defense in what might be a potentially precedent-setting medical cannabis insurance coverage case. CFAMM has been providing strategic support to Skinner and Aurora’s resources will ensure that Skinner can defend his case.

On January 30th, the Nova Scotia Human Rights Commission ruled that the Board of Trustees of the Canadian Elevator Industry Welfare Trust Fund committed discrimination by denying coverage for the medical cannabis Skinner uses to manage chronic pain and other conditions resulting from a work-related injury that left him permanently impaired. Following the decision, the Board of Trustees filed an appeal against Skinner and the Commission in the Nova Scotia Court of Appeal. The appeal has been set for October 2, 2017.

Founded in 2014, Canadians for Fair Access to Medical Marijuana (CFAMM) is a federal non-profit, patient-run organization dedicated to protecting and improving the rights of medical cannabis patients. CFAMM’s goal is to enable patients to obtain fair and safe access to medical cannabis with a special focus on affordability, including private and public insurance coverage.

We want to commend Aurora on its commitment to improving the cannabis industry and supporting patients in need. This decision may have a lasting impact on the sector and could change the landscape of the Canadian medical cannabis industry.


Disclaimer: Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

    0 1489

    2016 was a year to remember for Canadian licensed medical cannabis producers and investors had every reason to be excited early during 2017.

    However, the last two months have been painful for Canadian cannabis investors. But we believe this weakness has created great opportunities for investors. Although we do think the sub-sector has almost found a bottom, investors need to be selective and focus on companies that have a differentiated strategy and competitive advantage over its peers.

    Canada Continues to Expand its International Presence

    One of the ways Canadian licensed medical cannabis producers have been able to differentiate themselves from their peers is through he countries they are levered to.

    Canopy Growth Corp (WEED.TO) (TWMJF) Cronos Group (MJN.V) (PRMCF), and Aurora Cannabis (ACB.V) (ACBFF) have accomplished this very well and are levered to markets like Germany and Australia.

    The emerging legal cannabis industry has created ample opportunities from legal cannabis businesses across the globe and we believe that companies with a global presence are best positioned over the long-term.

    A Streaming Rally

    Since Monday, shares of Cannabis Wheaton (CBW.V) (KWFLF) are up more than 12% and this recent IPO has seemed to have found a bottom. We are favorable on the company’s differentiated strategy and believe it has secured some high-quality partners.

    Earlier this month, Cannabis Wheaton released the list of companies it has streaming deals with and we were very impressed with the quality of the roster of its clients, especially Broken Coast Cannabis Ltd. and Green Relief Inc.

    Cannabis Wheaton’s streaming partners include 14 outstanding companies located in six provinces across Canada. Of these companies, 2 have sales licenses (Broken Coast and Green Relief), 2 have cultivation licenses, 4 have affirmation letters and 6 are advanced pre-affirmation stage applicants.

    We are favorable on the recent improvement in trading volume as well as the associated rally and investors should keep Cannabis Wheaton on their radar.

    A Royal Deal in Oregon

    Earlier this week, CannaRoyalty Corp. (CRZ.CN: CSE) (CNNRF) announced that its investee, Rich Extracts, received a processing license from the Oregon Liquor Control Commission (OLCC) to begin producing and wholesaling cannabis products to licensed distributors and dispensaries throughout Oregon.

    CannaRoyalty previously advanced $2.3 million in debt to the company for the right to convert $2.15 million of the debt into a 30% royalty stream on Rich Extracts’ gross sales in perpetuity. The company is a fully integrated cannabis operator and has been focused on building and supporting a diversified portfolio of cannabis assets.

    Rich Extracts operates out of a 30,000-sq. ft. facility and produces cannabis extracts through a proprietary process. The company expected the OLCC to introduce new standards and started a new project to meet such standards. At full capacity, the facility can produce 80,000 grams of concentrates and distillates every month. Based on industry information, current wholesale prices for such products in Oregon range from $15-20 per gram.

    We are favorable on this development and continue to monitor CannaRoyalty as the shares have been under significant pressure (down 35% from April highs). The company’s United States symbol, CNNRF broke out of oversold territory last week and we are monitoring this unique Canadian cannabis firm.

    Author: Michael Berger

    Pursuant to an agreement between MAPH and Cannabis Wheaton, we were hired for a period of 30 days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH). We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

    0 3471

    The Canadian cannabis industry may have received the catalyst it needed…

    Yesterday, CBC News reported that the Liberal government will announce legislation next month that will legalize marijuana in Canada by July 1, 2018.

    This is a huge announcement as it was one of the main reasons why Justin Trudeau and the Liberal Party won the Canadian general election in 2015.

    CBC said it learned that the legislation will be announced during the week of April 10th and will broadly follow the recommendation of a federally appointed task force that was chaired by former liberal Justice Minister Anne McLellan.

    A Change of Words

    According to the CBC, Parliamentary Secretary to the Minister of Justice Bill Blair briefed the Liberal caucus on the roll-out plan and the legislation during caucus meetings this weekend.

    This is a big change from early March when Blair said the Canadian government will take as much time as it needs to correctly implement a legal recreational cannabis program. Blair previously did not suggest a specific time frame because he said it could vary from province-to-province and territory-to-territory

    An Industry to Watch

    The Canadian medical cannabis industry continues to record double-digit percentage growth on a month-over-month basis and has more than 100,000 patients. There are currently 38 federally licensed medical cannabis producers in Canada and we are favorable on the opportunity that these companies have on hand.

    We are favorable on this update and expect to see the market rally higher off this news. Some companies investors should watch include: Cronos Group (MJN.V) (PRMCF), Emblem Corp (EMC.V) (EMMBF), OrganiGram (OGI.V) (OGRMF), Canopy Growth (WEED.TO) (TWMJF), Aphria (APH.V) (APHQF), Aurora Cannabis (ACB.V) (ACBFF), and VinergyRes (VIN.CN) (VNNYF).

    Authored by: Michael Berger


    Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. An affiliate of MAPH Enterprises LLC owns 43,500 shares of EMBLEM as well as 21,750 Warrants


    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact
    Ad Placements